Coherus BioSciences Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
2024-11-05

* Coherus BioSciences Inc is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2024

* The Redwood City California-based company is expected to report a 20.6% decrease in revenue to $59.23 million from $74.57 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Coherus BioSciences Inc is for a loss of 12 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for Coherus BioSciences Inc is $8.00​, above​ its last closing price of $0.67. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.29 -0.29 -0.14 Beat 51.7

Mar. 31 2024 -0.25 -0.24 -0.32 Missed -32.3

Dec. 31 2023 -0.14 -0.12 -0.62 Missed -420.3

Sep. 30 2023 -0.29 -0.27 -0.27 Met 1.7

​​Jun. -0.48 -0.48 -0.38 Beat 21.6

30 2023

Jan. 1 0001 -0.54 -0.57 -0.75 Missed -31​

Dec. 31 2022 -0.87 -0.84 -0.60 Beat 28.4

Sep. 30 2022 -0.56 -0.57 -0.96 Missed -68.4

This summary was machine generated November 4 at 23:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10